Companies: 10,795·Total market cap: $144.5T
StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLSFOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$630018
P/E Ratio
52W High$0.03109
52W Low$0.0005

StageZero Life Sciences Ltd. (SZLSF) Revenue

Annual & quarterly revenue history · segment & region breakdown

SZLSF · revenue · updated Jun 15, 2026

Core revenue metrics

StageZero Life Sciences Ltd. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 25.12% year-over-year from $0.00B in FY2022.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
-25.12%
vs FY2022 $0.00B
Price / sales
0.29×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$54K
40 employees
FY2022
$0.00B
FY2021
$0.01B
5Y CAGR
+82.8%
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · StageZero Life Sciences Ltd. SEC filings · GAAPUpdated: 2026-06-15

Revenue trend

20222003 · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
2022-12-31$0.00B-$0.00B-25.12%
2021-12-31$0.01B+$0.00B+22.07%
2020-12-31$0.00B+$0.00B+2893.29%
2019-12-31$0.00B-$0.00B-25.38%
2018-12-31$0.00B-$0.00B-54.85%
2017-12-31$0.00B-$0.00B-60.95%
2016-12-31$0.00B+$0.00B+223.54%
2015-12-31$0.00B-$0.00B-84.58%
2014-12-31$0.00B+$0.00B+1602.71%
2013-12-31$0.00B-$0.00B-55.93%
SZLSF revenue by year · SZLSF revenue history · SZLSF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income StageZero Life Sciences Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

StageZero Life Sciences Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from StageZero Life Sciences Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

SZLSF revenue · 4 questions

SZLSF's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 25.12% year-over-year from $0.00B in FY2022.

SZLSF revenueSZLSF annual revenuewhat is SZLSF revenueSZLSF TTM revenue

Source: FMP · StageZero Life Sciences Ltd. SEC filings · GAAP · StageZero Life Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026